Abstract

Extracellular-vesicle-based cell-to-cell communication is conserved across all kingdoms of life. There is compelling evidence that extracellular vesicles are involved in major (patho)physiological processes, including cellular homoeostasis, infection propagation, cancer development and cardiovascular diseases. Various studies suggest that extracellular vesicles have several advantages over conventional synthetic carriers, opening new frontiers for modern drug delivery. Despite extensive research, clinical translation of extracellular-vesicle-based therapies remains challenging. Here, we discuss the uniqueness of extracellular vesicles along with critical design and development steps required to utilize their full potential as drug carriers, including loading methods, in-depth characterization and large-scale manufacturing. We compare the prospects of extracellular vesicles with those of the well established liposomes and provide guidelines to direct the process of developing vesicle-based drug delivery systems.

Keywords

Extracellular vesiclesExtracellular vesicleExtracellularVesicleDrug deliveryCell biologyIntracellularMicrovesiclesBiologyNanotechnologyChemistryBiochemistryMaterials scienceMembranemicroRNA

MeSH Terms

Drug Delivery SystemsExtracellular VesiclesHumans

Affiliated Institutions

Related Publications

Publication Info

Year
2021
Type
review
Volume
16
Issue
7
Pages
748-759
Citations
1613
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1613
OpenAlex
23
Influential

Cite This

Inge K. Herrmann, Matthew J. A. Wood, Gregor Fuhrmann (2021). Extracellular vesicles as a next-generation drug delivery platform. Nature Nanotechnology , 16 (7) , 748-759. https://doi.org/10.1038/s41565-021-00931-2

Identifiers

DOI
10.1038/s41565-021-00931-2
PMID
34211166

Data Quality

Data completeness: 90%